Back to Search Start Over

Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma

Authors :
Khê Hoang-Xuan
Jean-Yves Delattre
Yannick Marie
Fernando Lozano-Sanchez
Alexandre Carpentier
Marine Giry
François Ducray
Bertrand Mathon
Ahmed Idbaih
Jérôme Honnorat
Antoine Seyve
Matthieu Peyre
Suzanne Tran
Loïc Feuvret
Laurent Capelle
Karima Mokhtari
Alice Thomas
Marc Sanson
Hospices Civils de Lyon, Departement de Neurologie (HCL)
Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Sorbonne Université - Département de neurologie 2 - Mazarin
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Centre Paul Strauss
CRLCC Paul Strauss
Service de Neurochirurgie [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Sorbonne Université - Faculté de Médecine (SU FM)
Sorbonne Université (SU)
Service de Neuropathologie [CHU Pitié Salpêtrière]
Service de Radiothérapie [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Institut NeuroMyoGène (INMG)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Hospices Civils de Lyon (HCL)
Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Service d'Oncologie Radiothérapie [CHU Pitié Salpétrière]
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Source :
Clinical Neurology and Neurosurgery, Clinical Neurology and Neurosurgery, Elsevier, 2020, 196, pp.106006. ⟨10.1016/j.clineuro.2020.106006⟩
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

International audience; Objective: IDH wild-type glioblastoma is the most common and aggressive primary brain cancer in adults. At tumor recurrence, treatment decision-making is not standardized; several options include second surgery, reirradiation, and a second line of chemotherapy. In this retrospective monocentric study conducted at the era of WHO 2016 classification, we investigated IDH wild-type glioblastoma patients below the age of 70 to see (i) the clinical benefit of second surgery at recurrence and (ii) the prognostic factors in resected recurrent glioblastoma patients.Methods: 229 newly diagnosed IDH wild-type glioblastoma patients below the age of 70 treated with the standard of care (SOC) were enrolled in the current study and stratified into two subgroups according to treatment at recurrence: re-resection and no re-resection.Results: All experienced tumor recurrence with a median progression-free survival of 11 months. 25 % of patients were reoperated. Patients reoperated at recurrence had longer post-progression median overall survival compared to their non-reoperated counterparts (14 versus 9 months, p < .05). Initial surgical resection and a long time from the initial diagnosis to the first recurrence were independent prognostic factors for good outcomes in resected recurrent IDH-wild-type glioblastoma patients; however, tumor size before and after surgery did not impact post-surgical survival.Conclusion: Our study supports surgical resection at recurrence as therapeutic in IDH wild-type glioblastoma patients aged below 70 and in good clinical condition regardless of preoperative tumor size, particularly in patients who experienced a longer time before first recurrence and surgery at initial diagnosis. Further prospective and larger studies are warranted to validate our findings.

Details

ISSN :
03038467
Volume :
196
Database :
OpenAIRE
Journal :
Clinical Neurology and Neurosurgery
Accession number :
edsair.doi.dedup.....f758460ecf1a623111e62356cebe4de4
Full Text :
https://doi.org/10.1016/j.clineuro.2020.106006